Cited by 637Psychedelics and Drug StudiesParanormal Experiences and BeliefsReligion, Spirituality, and Psychology

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Open access

Barrett, Frederick S, Johnson, Matthew W, Griffiths, Roland R·2015·Journal of Psychopharmacology

DOI 10.1177/0269881115609019PMC PMC5203697

Open this paper in CoChat — free account

Abstract

The 30-item revised Mystical Experience Questionnaire (MEQ30) was previously developed within an online survey of mystical-type experiences occasioned by psilocybin-containing mushrooms. The rated experiences occurred on average eight years before completion of the questionnaire. The current paper validates the MEQ30 using data from experimental studies with controlled doses of psilocybin. Data were pooled and analyzed from five laboratory experiments in which participants ( n=184) received a moderate to high oral dose of psilocybin (at least 20 mg/70 kg). Results of confirmatory factor analysis demonstrate the reliability and internal validity of the MEQ30. Structural equation models demonstrate the external and convergent validity of the MEQ30 by showing that latent variable scores on the MEQ30 positively predict persisting change in attitudes, behavior, and well-being attributed to experiences with psilocybin while controlling for the contribution of the participant-rated intensity of drug effects. These findings support the use of the MEQ30 as an efficient measure of individual mystical experiences. A method to score a “complete mystical experience” that was used in previous versions of the mystical experience questionnaire is validated in the MEQ30, and a stand-alone version of the MEQ30 is provided for use in future research.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/0269881115609019

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

R: A Language and Environment for Statistical Computing
R Core Team (2000) · doi:10.32614/r.manuals · Cited by 355,893
Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives
Hu, L., & Bentler, P. M. (1999) · Structural Equation Modeling A Multidisciplinary Journal · doi:10.1080/10705519909540118 · Cited by 108,788
lavaan : An R Package for Structural Equation Modeling
Rosseel, Y. (2012) · Journal of Statistical Software · doi:10.18637/jss.v048.i02 · Cited by 27,955
Alternative Ways of Assessing Model Fit
Browne, M. W., & Cudeck, R. (1992) · Sociological Methods & Research · doi:10.1177/0049124192021002005 · Cited by 27,200
Confirmatory factor analysis for applied research
Brown, T. A. (2007) · Choice Reviews Online · doi:10.5860/choice.44-2769 · Cited by 15,621
Testing Structural Equation Models.
Mueller, C. W., Bollen, K. A., & Long, J. S. (1994) · Contemporary Sociology A Journal of Reviews · doi:10.2307/2074955 · Cited by 14,211
EQS : structural equations program manual
Bentler, P. M. (1989) · Medical Entomology and Zoology · Cited by 9,669
Detection Theory: A User's Guide
Macmillan, N. A., & Creelman, C. D. (1991) · Cited by 5,415
A scaled difference chi-square test statistic for moment structure analysis
Satorra, A., & Bentler, P. M. (2001) · Psychometrika · doi:10.1007/bf02296192 · Cited by 5,282
The varieties of religious experience: A study in human nature.
James, W. (1902) · doi:10.1037/10004-000 · Cited by 5,204

Show all 34 references

Research works printed but not linked: 3

Pahnke WN, 1963, Drugs and Mysticism: An Analysis of the Relationship Between Psychedelic Drugs and the Mystical Consciousness
Pahnke WN, 1967, LSD Man & Society, 60
Richards WA, 1975, Counseling, Peak Experiences and the Human Encounter with Death: An Empirical Study of the Efficacy of DPT-Assitance Counseling in Enhancing Quality of Life of Persons with Terminal Cancer and Their Closest Family Members

Sorted by citations

Items 301–400 of 635

Phenomenology of Psychedelic Experiences and Psychedelic-Associated Distressing Effects: Quantifying Subjective Experiences
Costines, C., & Schmidt, T. T. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_562 · Cited by 12
Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review
Erkizia-Santamaría, I., Horrillo, I., Meana, J. J., & Ortega, J. E. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111249 · Cited by 12
Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial
Wießner, I., Falchi-Carvalho, M., Laborde, S., Barros, H., Bolcont, R., Silva, S. R. B., Pantrigo, É. J., Medina, M., Arichelle, F., de Almeida, R. N., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.06.002 · Cited by 9
Evidence versus expectancy: the development of psilocybin therapy
Rucker, J. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.28 · Cited by 9
Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching, T. H. W., Amoroso, L., Bohner, C., D’Amico, E. J., Eilbott, J. A., Entezar, T., Fitzpatrick, M., Fram, G., Grazioplene, R. G., Hokanson, J., et al. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1278823 · Cited by 10
Psychological and physiological effects of extended DMTPreprint
Luan, L. X., Eckernäs, E., Ashton, M., Rosas, F. E., Uthaug, M. V., Bartha, A., Jagger, S., Perai, K. G., Gomes, L., Nutt, D. J., et al. (2023) · doi:10.31234/osf.io/vg4dp · Cited by 9
Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use
Brett, J., Knock, E., Watson, K., Albert, S., Siefried, K. J., & Guss, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1490907 · Cited by 7
“During subsequent self-assessment, she scored >60% on each of the seven subscales of the mystical experience questionnaire, indicating a “ complete mystical experience ” (20) and scored a total of 80 out of 100 on the emotional break through inventory (21).”
Cross-validation of the ego dissolution scale: implications for studying psychedelics
Lynn, S. J., McDonald, C. W., Sleight, F. G., & Mattson, R. E. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267611 · Cited by 10
Documenting and defining emergent phenomenology: theoretical foundations for an extensive research strategy
Sandilands, O., & Ingram, D. M. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1340335 · Cited by 10
Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports
Žuljević, M. F., Mijatović, A., Marušić, S. L., Kudrjavets, G., Buljan, I., & Hren, D. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2274382 · Cited by 8
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial
Bhagavan, C., Glue, P., Evans, W., Reynolds, L., Turner, T., King, C., Russell, B. R., Morunga, E., Mills, J. L., Layton, G., et al. (2024) · Trials · doi:10.1186/s13063-024-08174-x · Cited by 10
Positive Affect and Letheby's Naturalization of Psychedelic Therapy
Hoffman, S. (2022) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2022.9285 · Cited by 7
Do Psychedelic Trips Open the Door to Messages from God, Spirits, Transcendent Realities, or the Devil? Links with Attitudes About Psychedelics, Opinions About Legalization, and Interest in Personal Use
Exline, J. J., Schutt, W. A., Pait, K. C., & Wilt, J. A. (2022) · International Journal for the Psychology of Religion · doi:10.1080/10508619.2022.2148062 · Cited by 8
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study.
Knock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
An examination of internal family systems interventions for trauma with implications for ethical psychedelic-assisted treatment
Earleywine, M., Oliva, A. B., Leo, J. A. D., & Banks, R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00265 · Cited by 8
Developing a short form of the Awe Experience Scale (AWE-SF) in psychedelic samples
Graziosi, M., Rohde, J. S., Lake, S., Lucas, P., Kaufman, S. B., & Yaden, D. B. (2024) · PLoS ONE · doi:10.1371/journal.pone.0314469 · Cited by 10
Integration of personal psychedelic experiences into clinical practice: A phenomenological study in mental health professionals
Tadmor, N., Halperin, D., & Simon, G. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00372 · Cited by 7
Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes
Hooper, J., Gyongyosi, E., Hutchison, K. E., & Mueller, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1533055 · Cited by 7
Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double‐Blind, Placebo‐Controlled, Crossover Study
Arikci, D., Holze, F., Mueller, L., Vizeli, P., Rudin, D., Luethi, D., Hysek, C. M., & Liechti, M. E. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3726 · Cited by 7
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies
Roseby, W., Kettner, H., Roseman, L., Spriggs, M. J., Lyons, T., Peill, J., Giribaldi, B., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1580663 · Cited by 8
Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study
Millón, M. B. B., Noguera, L., Bruno, D., Vita, L., Zanino, M., Kassuha, D., Ortiz, J. E., Feresin, G. E., Díaz-Dellavalle, P., Orosco, L. L., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02167-3 · Cited by 7
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 7
The Psychology of Mysticism
Chen, Z. J. (2026) · Cambridge University Press eBooks · doi:10.1017/9781009420860 · Cited by 7
"EVERYTHING IS CONNECTED": NETWORKED CONSPIRITUALITY IN NEW AGE MEDIA
Chia, A., Ong, J. C., Davies, H. T., & Hagood, M. (2021) · AoIR Selected Papers of Internet Research · doi:10.5210/spir.v2021i0.12093 · Cited by 7
A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder
Escamilla-Orozco, R. I., González-Trujano, M. E., Mariscal, J. M. G., Torres-Valencia, J. M., Guzmán-González, H., Vega, J. L., & Loizaga-Velder, A. K. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2246459 · Cited by 7
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Kovacevich, A., Weleff, J., Claytor, B., & Barnett, B. S. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2253538 · Cited by 7
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani, A., Alexander, J. L., Sumner, C. R., Pine, J. H., Gross, L. S., Raison, C. L., Aaronson, S. T., & Baron, D. A. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000729 · Cited by 7
Development of the Japanese version of the 30‐item Mystical Experience Questionnaire
Yonezawa, K., Tani, H., Nakajima, S., & Uchida, H. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12377 · Cited by 6
Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study
Lancelotta, R., DellaCrosse, M. A., Quinn, D., Saniyah, S., Saniyah, M., Gukasyan, N., Narayan, S. K., Nikolaidis, A., Sevelius, J. M., & Davis, A. K. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2520224 · Cited by 7
Naturalism and the hard problem of mysticism in psychedelic science
Jylkkä, J. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1112103 · Cited by 7
An exploration of the roles of trauma and dissociation in mystical experiences and near-death experiences
Nobakht, H. N., & Dale, K. Y. (2018) · Journal of Spirituality in Mental Health · doi:10.1080/19349637.2018.1439796 · Cited by 7
Psychedelic Mysticism and Christian Spirituality: From Science to Love
Cole‐Turner, R. (2024) · Religions · doi:10.3390/rel15050537 · Cited by 6
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
Irrmischer, M., Puxty, D. J., Yıldırım, B. O., Deijen, J. B., & Engelbregt, H. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06733-3 · Cited by 7
Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111300 · Cited by 7
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression
Brudner, R. M., Kaczmarek, E. S., Blainey, M. G., Schulz-Quach, C., Meshkat, S., Doyle, Z., Lipsitz, O., Offman, H., Sethi, R., Weiglein, G., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251346697 · Cited by 10
Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis
Cheung, K., Propes, C., Graziosi, M., Patch, K., & Yaden, D. B. (2025) · AJOB Empirical Bioethics · doi:10.1080/23294515.2025.2526339 · Cited by 6
The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research
Stocker, K., Hartmann, M., Schmid, Y., Vogt, S. B., Becker, A., Ley, L., Straumann, I., Arikci, D., Klaiber, A., Erne, L., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251397328 · Cited by 9
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland
Brakha, T. A., Buchard, A., Mabilais, C., Alaux, S., Amberger, C., Furtado, L., Seragnoli, F., Briefer, J.-F., Thorens, G., Sabé, M., et al. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.116992 · Cited by 6
Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder
Ehrenkranz, R. C., Agrawal, M., Penberthy, J. K., & Yaden, D. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357668 · Cited by 6
Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2375720 · Cited by 6
The METEMP protocol: Massed exposure therapy enhanced with MDMA for PTSD
Maples‐Keller, J. L., Dunlop, B. W., & ROTHBAUM, B. O. (2024) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2024.101400 · Cited by 7
Differential relationship between meditation methods and psychotic-like and mystical experiences
Palmer, T. N., Kadri, K., Fakra, É., Scholl, J., & Fouragnan, E. F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309357 · Cited by 7
The Hallucinogen Rating Scale: Updated Factor Structure in a Large, Multistudy Sample
Calder, A. E., Qualls, C., Hasler, G., Elmiger, D., & Strassman, R. J. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100436 · Cited by 7
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 7
EcoMeditation Modifies Brain Resting State Network Activity.
Stapleton, P., Church, D., Baumann, O., & Sabot, D. (2022) · PubMed Central · Cited by 6
Validation of the Danish Translation of the Revised Mystical Experience Questionnaire (MEQ30) and Possible Impact of Setting, Dose and Intention
Hovmand, O. R., Jensen, M. E., Juul, T. S., Madsen, M. K., Fisher, P. M., & Stenbæk, D. S. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2302186 · Cited by 6
Leveraging meditation research for the study of psychedelic-related adverse effects
Palitsky, R., Canby, N. K., Dam, N. T. V., Levin-Aspenson, H. F., Kaplan, D. M., Maples‐Keller, J. L., Raison, C. L., Grant, G. H., Dunlop, B. W., & Britton, W. B. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2420745 · Cited by 7
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104
Ludbrook, G., Bryson, N., Taylor, B., Hocevar‐Trnka, J., Johnson, M. W., Hirman, J., Morrish, G. A., Alexander, R., & Pollack, M. H. (2025) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002047 · Cited by 5
Self-citation
Religious and spiritual experiences from a neuroscientific and complex systems perspective
Jedlička, P., & Havenith, M. N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106319 · Cited by 15
The emotional architecture of the psychedelic brain
Moujaes, F., Rieser, N. M., Belinger, L., Herdener, M., Zahid, Z., & Preller, K. H. (2025) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2025.07.006 · Cited by 5
Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants
Straumann, I., Vizeli, P., Avedisian, I., Erne, L., Noorshams, D., Vukalović, I., Eckert, A., Luethi, D., Rudin, D., & Liechti, M. E. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02248-3 · Cited by 8
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review
Viljoen, G., Walter, H., Bendau, A., Koslowski, M., & Betzler, F. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389581 · Cited by 8
Psychology of mysticism: Toward a layered hierarchy model
Chen, Z. J. (2024) · Archive for the Psychology of Religion · doi:10.1177/00846724241255129 · Cited by 9
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm
MacConnel, H. A., Earleywine, M., & Radowitz, S. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241286726 · Cited by 8
The phenomenology of psychedelic temporality: current knowledge, open questions, and clinical applications
McMillan, R. M., Reynolds, J., & Fernandez, A. V. (2024) · Philosophical Psychology · doi:10.1080/09515089.2024.2433522 · Cited by 5
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain
Levin, A. W. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241303599 · Cited by 5
Dynamic medial parietal and hippocampal deactivations under DMT relate to sympathetic output and altered sense of time, space, and the self
Pasquini, L., Simon, A. J., Gallen, C. L., Kettner, H., Roseman, L., Gazzaley, A. H., Carhart-Harris, R. L., & Timmermann, C. (2025) · Imaging Neuroscience · doi:10.1162/imag_a_00541 · Cited by 5
Translation and Initial Psychometric Evaluation of Spanish Versions of Three Psychedelic Acute Effects Measures: Mystical, Challenging, and Insight Experiences
Davis, A. K., Timmermann, C., Bernal, A. M. O., Lancelotta, R., Nayak, S. M., Sepeda, N. D., Nikolaidis, A., & Griffiths, R. R. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2232379 · Cited by 5
Self-citation
Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development
Weintraub, M. J., Jeffrey, J. K., Grob, C. S., Ichinose, M. C., Bergman, R. L., Cooper, Z. D., & Miklowitz, D. J. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0018 · Cited by 5
Expectancies for Subjective and Antidepressant Effects in Psilocybin Users
Earleywine, M., Mian, M. N., & Leo, J. A. D. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231194798 · Cited by 5
Trajectories of sentiment in 11,816 psychoactive narratives
Friedman, S. F., & Ballentine, G. (2023) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2889 · Cited by 5
Both partners practicing orgasmic meditation report having a mystical-type experience: results using the Mystical Experience Questionnaire
Siegel, V., & Emmert‐Aronson, B. O. (2021) · F1000Research · doi:10.12688/f1000research.53496.1 · Cited by 3
The moderating role of mystical-type experiences on the relationship between existential isolation and meaning in life
Sielaff, A., Horner, D. E., & Greenberg, J. (2021) · Personality and Individual Differences · doi:10.1016/j.paid.2021.111347 · Cited by 5
Sleep-like state during wakefulness induced by psychedelic 5-MeO-DMT in micePreprint
Bréant, B. J. B., Prius-Mengual, J., Hoerder-Suabedissen, A., Patel, J., Bannerman, D. M., Sharp, T., & Vyazovskiy, V. V. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.11.519886 · Cited by 5
Naturalistic Psilocybin Use Increases Mind Perception but not Atheist-Believer status: A Prospective Longitudinal StudyPreprint
Nayak, S. M., White, S. S., Hilbert, S. N., Lowe, M. X., Jackson, H., Griffiths, R. R., Garcia‐Romeu, A., & Yaden, D. B. (2023) · doi:10.31234/osf.io/auycp · Cited by 5
Self-citation
The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s JourneyPreprint
Brouwer, A., Brown, J. K., Erowid, E., Erowid, F., Thyssen, S., Raison, C. L., & Carhart-Harris, R. L. (2024) · Research Square · doi:10.21203/rs.3.rs-3941205/v1 · Cited by 5
Psilocybin’s acute and persistent brain effects: a precision imaging drug trial
Subramanian, S., Reneau, T. R., Perry, D., Chacko, R. V., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J. A., Metcalf, N. V., Lenze, E. J., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05189-0 · Cited by 6
Improvements in well-being following naturalistic psychedelic use and underlying mechanisms of change in older adults: A prospective cohort studyPreprint
Kettner, H., Roseman, L., Gazzaley, A., Carhart-Harris, R., & Pasquini, L. (2024) · Research Square · doi:10.21203/rs.3.rs-3977169/v1 · Cited by 5
Patterns of Internalizing Problems, Substance Use and Cognitive Flexibility Before and After Naturalistic Psilocybin Use: A Repeated Measures Latent Profile Analysis
Richard, J., Scott, J., Nayak, S. M., Sepeda, N. D., Lowe, M. X., Jackson, H., & Garcia‐Romeu, A. (2025) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-025-01489-z · Cited by 4
Psychedelic assemblages
Falcon, J. (2025) · Critique of Anthropology · doi:10.1177/0308275x251357813 · Cited by 4
A causal pluralist theory of the interaction of substance, set and setting in psychedelic experience
Kiverstein, J. D., Beyköylü, H., & van Elk, M. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2590741 · Cited by 4
Development of the Japanese version of the Challenging Experience Questionnaire
Tani, H., Yonezawa, K., Kusudo, K., Barrett, F. S., Nakajima, S., & Uchida, H. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12456 · Cited by 3
Self-citation
Centering and flourishing: an online intervention study assessing the effects of a Christian contemplative practice on stress-reduction and human flourishing
Rohde, J. S., Goldy, S. P., Graziosi, M., Ferguson, M. A., Thrul, J., & Yaden, D. B. (2024) · BMC Psychology · doi:10.1186/s40359-024-01836-0 · Cited by 5
Feasibility of a Hypnosis Intervention for a Mystical Experience
Corlett, C. E., Alldredge, C. T., & Elkins, G. R. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2491352 · Cited by 5
A Case Study of the METEMP Protocol: Massed Exposure Therapy Enhanced With 3,4-Methylenedioxymethamphetamine (MDMA) for Posttraumatic Stress Disorder
Maples‐Keller, J. L., & ROTHBAUM, B. O. (2025) · Cognitive and Behavioral Practice · doi:10.1016/j.cbpra.2025.02.001 · Cited by 4
Should we skip the trip? Clinical implications of psychedelic-associated subjective effects and the potential role of non-hallucinogenic alternatives
Bhatt, K. V., Asuncion, J. D., Alam, A., Zisook, S., & Stahl, S. M. (2025) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2025.07.001 · Cited by 4
Meditation and psychedelics facilitate similar types of mystical, psychological, and philosophical-existential insights predictive of wellbeing: a qualitative-quantitative approach
Jylkkä, J., Väyrynen, H., Lin, E., Walldén, C., Krabbe, A., Kähönen, J., & Sikka, P. (2025) · Consciousness and Cognition · doi:10.1016/j.concog.2025.103901 · Cited by 7
N, N-Dimethyltryptamine (DMT)-Occasioned Familiarity and the Sense of Familiarity Questionnaire (SOF-Q)
Lawrence, D. W., Battista, A. P. D., & Timmermann, C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2230568 · Cited by 4
A Psychometric Evaluation of the Dutch Revised Mystical Experience Questionnaire
Wirsching, A., Bostoen, T., & Huizink, A. C. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2272832 · Cited by 4
Silence between words: Is solitude important for relatedness?
Costa, R. M. (2024) · Progress in brain research · doi:10.1016/bs.pbr.2024.05.013 · Cited by 4
Belief change and agnostic frames in psychedelic research and clinical contexts
Yaden, D. B., Nayak, S. M., & Griffiths, R. R. (2024) · Oxford University Press eBooks · doi:10.1093/oso/9780192898371.003.0008 · Cited by 4
Self-citation
Acute Psychedelic Reactions, Post-Acute Changes in Dysfunctional Attitudes, and Psychedelic-Associated Changes in Wellbeing
Earleywine, M., Falabella, G. S., Oliva, A. B., & Low, F. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2421892 · Cited by 4
Psilocybin-Assisted Therapy May Enhance Conservation Values in Patients with Alcohol Use Disorder
Gold, N. D., Pagni, B. A., Petridis, P. D., & Bogenschutz, M. P. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0030 · Cited by 4
A prospective ecological momentary assessment study of an ayahuasca retreat: exploring the salutary impact of acute psychedelic experiences on subacute affect and mindfulness skills in daily life
Sznitman, S. R., Behar, Y. A., Dicker‐Oren, S. D., Shochat, T., Meiri, D., Butto, N., Roe, D., & Bernstein, A. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06704-8 · Cited by 4
Comparing psychedelic and meditation experience reports with natural language processing
Kallio-Mannila, K., Salmela, R., & Jylkkä, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-27724-0 · Cited by 3
Practices in Religious Naturalism
Steinhart, E. C. (2018) · Routledge eBooks · doi:10.4324/9781315228907-30 · Cited by 4
Serotonin and serotonin receptors in hallucinogen action
Halberstadt, A. L., & Nichols, D. E. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00043-8 · Cited by 4
The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016)
Bouso, J. C., Pérez, E. J. P., Gandy, S., & Alcázar‐Córcoles, M. Á. (2017) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2570 · Cited by 5
Natural Language as a Window into the Subjective Effects and Neurochemistry of Psychedelic DrugsPreprint
Tagliazucchi, E. (2021) · Preprints.org · doi:10.20944/preprints202111.0201.v1 · Cited by 3
Recreational Psychedelic Users Frequently Encounter Complete Mystical Experiences: Trip Content and Implications for WellbeingPreprint
Qiu, T. T., & Minda, J. P. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/xrbzs · Cited by 7
Belief changes associated with psychedelic usePreprint
Nayak, S. M., Singh, M., Yaden, D. B., & Griffiths, R. R. (2022) · doi:10.31234/osf.io/rdzmy · Cited by 4
Self-citation
Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical TrialPreprint
Lewis, B. R., Hendrick, J., Byrne, K., Odette, M. M., Wu, C., & Garland, E. L. (2025) · medRxiv · doi:10.1101/2024.12.31.24319806 · Cited by 4
An Integrative Review of Measures of Spirituality in Experimental Studies of Psilocybin in Serious Illness Populations
Baker, K. M., Ulrich, C. M., & Meghani, S. H. (2023) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/10499091221147700 · Cited by 4
Factor analysis of the MEQ43 suggests non-psychedelic mystical experiences are different from psychedelic mystical experiences
Formoso, K. A. (2023) · Consciousness Spirituality & Transpersonal Psychology · doi:10.53074/cstp.2023.63 · Cited by 3
Ketamine's Altered States Meta-Analysis
Tavares, V. D. D. O., Gonçalves, K. T. D. C., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Nunes, E. A., Sarris, J. J., Perkins, D., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001946 · Cited by 3
Evaluation of the peak experience scale as a rapid assessment tool for the strength of a psychoactive experience with 5-MeO-DMT
Reckweg, J. T., Mason, N. L., Theunissen, E. L., Svendsen, C. B., Terwey, T. H., & Ramaekers, J. G. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1543640 · Cited by 5
Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework
Modlin, N. L., Williamson, V., Maggio, C., Stubley, J., Kirlić, N., Cleare, A. J., & Rucker, J. (2025) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251342319 · Cited by 3
Complementary therapies for chronic knee pain: A placebo-controlled RCT of Reiki and mindfulness
Hanley, A. W., Nakamura, Y., Edwards, R. R., Lingard, A., Childs, K., Faulkner, J., Schnitt, R., Claire, S. V.-S., Bridge, E., & Garland, E. L. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103278 · Cited by 3
Exploring Mystical-Type Experiences Through Auto-Induced Cognitive Trance
Bicego, A., Alnagger, N., Cardeña, E., Sombrun, C., Martial, C., Annen, J., Gosseries, O., & Vanhaudenhuyse, A. (2025) · International Journal of Clinical and Experimental Hypnosis · doi:10.1080/00207144.2025.2544055 · Cited by 4

Authors: Barrett, F. S., Johnson, M. W., & Griffiths, R. R.
Affiliations: Johns Hopkins University (US)
Corresponding author: Barrett, Frederick S
ORCID: Barrett, Frederick S
Johnson, Matthew W
Griffiths, Roland R
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2015-10-06
Volume: 29
Issue: 11
Pages: 1182-1190
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881115609019
PMC: PMC5203697
OpenAlex: W2340085151
Cited by: 637
References: 34
Citations by year: 2026: 91 · 2025: 110 · 2024: 123 · 2023: 78 · 2022: 78 · 2021: 53 · 2020: 38 · 2019: 12 · 2018: 20 · 2017: 21 · 2016: 12
FWCI: 21.94
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute on Drug Abuse (R01DA003889, T32DA007209, R01DA03889)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
Social Sciences › Health › Religion, Spirituality, and Psychology
Keywords: psilocybin, mystical experience, psychedelic drug effects, questionnaire validation, factor structure, convergent validity, attitude change, well-being
MeSH terms: Administration, Oral, Hallucinogens, Humans, Mysticism, Psilocybin, Surveys and Questionnaires

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks